Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study

Απλή σελίδα τεκμηρίου
dc.contributor.authorAravantinos, G.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorKosmidis, P.en
dc.contributor.authorDimopoulos, M. A.en
dc.contributor.authorStathopoulos, G. P.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorBafaloukos, D.en
dc.contributor.authorPapadimitriou, C.en
dc.contributor.authorKarpathios, S.en
dc.contributor.authorGeorgoulias, V.en
dc.contributor.authorPapakostas, P.en
dc.contributor.authorKalofonos, H. P.en
dc.contributor.authorGrimani, E.en
dc.contributor.authorSkarlos, D. V.en
dc.date.accessioned2015-11-24T19:00:08Z
dc.date.available2015-11-24T19:00:08Z
dc.identifier.issn0923-7534-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19485
dc.rightsDefault Licence-
dc.subjectAntineoplastic Combined Chemotherapy Protocols/administration & dosage/adverseen
dc.subjecteffects/*therapeutic useen
dc.subjectCarboplatin/administration & dosageen
dc.subjectCisplatin/administration & dosageen
dc.subjectDisease-Free Survivalen
dc.subjectDrug Administration Scheduleen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectOvarian Neoplasms/*drug therapyen
dc.subjectPaclitaxel/administration & dosageen
dc.subjectPatient Complianceen
dc.subjectProspective Studiesen
dc.subjectSurvival Analysisen
dc.titlePaclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) studyen
heal.abstractBACKGROUND: We compared the combination plus Carboplatin plus paclitaxel, which is considered the treatment of choice for initial chemotherapy of advanced ovarian cancer (AOC) with a regimen combining alternating carboplatin and cisplatin plus paclitaxel. The two platinum derivatives have been previously combined as they are not totally cross-resistant and as they share no overlapping toxicities. PATIENTS AND METHODS: Patients with AOC, after the initial cytoreductive surgery were randomized to either 6 courses of paclitaxel at 175 mg/m2 as 3 h infusion plus Carboplatin at 7 AUC (Arm A) or Paclitaxel at the same dose plus Carboplatin again at 7 AUC for cycles 1,3,5, while for cycles 2,4,6 Cisplatin at 75 mg/m2 substituted for Carboplatin (Arm B). RESULTS: 247 patients are analyzed. Significant differences were not found, both in terms of PFS (38 vs 39 months, p=0.95) and overall survival (40.6 vs 38.6 months, p=0.79). There was not also difference in 5-year survival rate (35% vs 39%) or 5-year PFS rate (23% vs 28%). Age >60, PS 2, stage IV disease and presence of residual disease were adversely related to the overall survival. CONCLUSION: Both regimens are well tolerated and effective. Alternating cisplatin with carboplatin does not improve the results compared with the standard combination.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1093/annonc/mdi223-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/15928071-
heal.identifier.secondaryhttp://annonc.oxfordjournals.org/content/16/7/1116.full.pdf-
heal.journalNameAnn Oncolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2005-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ